Outstanding *JNMT* Articles for 2007

Frances Neagley, CNMT, FSNMTS, editor-in-chief of the *Journal of Nuclear Medicine Technology* (*JNMT*), presented awards at the 2008 SNM Annual Meeting to the authors of 3 articles chosen as the most outstanding 2007 contributions to *JNMT*. The lead authors or their representatives received plaques and honoraria in a ceremony held during the annual business meeting of the SNMTS on June 17 in New Orleans, LA. Douglass C. Vines, Harald Keller, Jeremy D.P. Hoisak, and Stephen L. Breen from the University of Toronto (Canada) received the first-place award for "Quantitative PET comparing gated with nongated acquisitions using a NEMA phantom with respiratory-simulated motion" (*J Nucl Med Technol*. 2007;354:246–251). The second-place award went to Narihiro Hara, Teruhiko Takayama, Masahisa Onoguchi, Norikazu Obane, Toshiaki Miyati, Toshiaki Yoshioka, Katsuhiko Sakaguchi, and Minoru Honda from Sumitomo Hospital (Osaka, Japan) for "Subtraction SPECT for parathyroid scintigraphy based on maximization of mutual information" (*J Nucl Med Technol*. 2007;35:84–90). The third-place award was presented to Martha V. Mar, Scott A. Miller, E. Edmund Kim, and Homer A. Macapinlac from the University of Texas M.D. Anderson Cancer Center (Houston) for "Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging" (*J Nucl Med Technol*. 2007;35:10–16).

Frances Neagley presents Douglass Vines, first place winner, with the *JNMT* Award

"These papers represent the broad range of investigative endeavors—across the spectrum of clinical, radiopharmaceutical, technological, and basic sciences—in which nuclear medicine technologists are involved today," said Neagley. "We congratulate this year's awardees and all those whose contributions continue to make *JNMT* a vital resource that is constantly evolving to meet the changing scientific and professional needs of our readers."

LETTERS TO THE EDITOR

To the Newsline Editor:

In the article summarizing my remarks at the SNM Molecular Imaging Summit and published in the June issue of Newsline (2008;49:65N−68N), the baseball field used in the film *Field of Dreams* was referred to as having been plowed under to grow corn and soybeans. An analogous fate would be unwelcome for molecular imaging and therapy, our own field of dreams. On June 19, I spoke with Betty Lansing, one of the original owners of part of the field used in the film. She advised me that although the left field area of the diamond had at one time been plowed under by its other owner, the Lansing family has now acquired the entire field. Thus the full field of dreams has been restored and is now ready for visitors.

Three additional clarifications should be made to this article. Rituximab sales currently total more than $4 billion per year (not $200 million). I am one of the inventors on several patents used for Zevalin (and Bexxar) and licensed from the University of Michigan under an arrangement managed by the Office of Policy Coordination at Johns Hopkins. In addition, as a result of the bipartisan July 15 U.S. Senate and House votes overriding a presidential veto of the Medicare Improvements for Patients and Providers Act of 2008, Medicare reimbursement for Zevalin will not be as low as originally proposed by the Centers for Medicare & Medicaid Services. This act preserves payments for physicians and also avoids for the next 18 mo the proposed severe cuts in reimbursement for radioimmunotherapies, which should help to continue to make these available to patients.

Let us be hopeful that our nuclear medicine field of dreams remains intact and flourishes as well.

Richard Wahl, MD
Professor of Radiology and Oncology
Henry N. WagnerJr., Professor of Nuclear Medicine
Director of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD